Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Merck
Cipla
AstraZeneca
Fuji
Federal Trade Commission
McKinsey
UBS
Teva

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208673

« Back to Dashboard

NDA 208673 describes SOLIQUA 100/33, which is a drug marketed by Sanofi-aventis Us and is included in one NDA. It is available from one supplier. There are twenty-two patents protecting this drug. Additional details are available on the SOLIQUA 100/33 profile page.

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. There are thirty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.
Summary for 208673
Tradename:SOLIQUA 100/33
Applicant:Sanofi-aventis Us
Ingredient:insulin glargine; lixisenatide
Patents:22
Formulation / Manufacturing:see details
Pharmacology for NDA: 208673
Suppliers and Packaging for NDA: 208673
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673 NDA Sanofi-Aventis U.S. LLC 0024-5761 N 0024-5761-05

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML)
Approval Date:Nov 21, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 27, 2021
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Nov 21, 2019
Regulatory Exclusivity Use:NEW COMBINATION
Patent:➤ Sign UpPatent Expiration:Sep 23, 2027Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
US Department of Justice
McKesson
Daiichi Sankyo
Fuji
Mallinckrodt
Chinese Patent Office
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot